Several NASH therapies are in late development stages, with potential to address growing unmet need

NASH is the unnatural build-up of fat in the liver as part of non-alcoholic fatty liver disease (NAFLD), causing inflammation and leading to fibrosis and cirrhosis of the liver. NASH prevalence is 10 million, or 18% of the EU population and its prevalence in European countries is expected to increase by more than 40% by 2030. It is becoming the leading cause for liver transplants.


What is the potential breakthrough?

Both PPARα/β/δ and FXR agonists will be the first ever therapies for NASH and are expected to reduce liver fat build up, inflammation and fibrosis.

How will it help patients?
These new products promise to reverse disease progression resulting in a significant improvement in patient prognosis and reducing the need to undergo liver transplantation. Up to 15% of patients may be able to avoid liver transplant, as new therapies can reverse disease pathology; this translates to ~13.500 fewer transplants in Europe in the current patient population.


What is the potential impact on Europe’s healthcare systems?

The ability to reverse disease progression would see fewer patients requiring costly liver transplants and treatment associated with liver failure complications, resulting in cost savings for the HC system of ~€1,4bn.

What is the potential impact on societies?

The significant reduction in debilitating complications and time spent receiving care will reduce absenteeism, improving economic productivity.

Therapies for NASH (Non-Alcoholic Steatohepatitis) have the potential to reduce the build up of fat in the liver, which could avoid up to 12,000 transplants in Europe each year

Download the full IQVIA/EFPIA Pipeline Review 2021

mobile feature article image